SAN DIEGO and PENNINGTON, N.J., April
29, 2019 /PRNewswire/ -- OncoSec Medical Incorporated
(OncoSec) (NASDAQ: ONCS), a company developing late-stage
intratumoral cancer immunotherapies, today announced that
Daniel J. O'Connor, President and
Chief Executive Officer of OncoSec, will present a company overview
at the ThinkEquity Conference 2019 on Thursday, May 2, 2019, at 11:30 a.m. ET in New York, NY.
A live audio webcast of the presentation will be available on
the Investors section of OncoSec's website at ir.oncosec.com, where
it will be archived for approximately 30 days.
About OncoSec Medical Incorporated
OncoSec is a
clinical-stage biotechnology company focused on developing
cytokine-based intratumoral immunotherapies to stimulate the body's
immune system to target and attack cancer. OncoSec's lead
immunotherapy platform – TAVO™ (tavokinogene telseplasmid) –
enables the intratumoral delivery of DNA-based interleukin-12
(IL-12), a naturally occurring protein with immune-stimulating
functions. The technology, which employs electroporation, is
designed to produce a controlled, localized expression of IL-12 in
the tumor microenvironment, enabling the immune system to target
and attack tumors throughout the body. OncoSec has built a deep and
diverse clinical pipeline utilizing TAVO™ as a potential treatment
for multiple cancer indications either as a monotherapy or in
combination with leading checkpoint inhibitors; with the latter
potentially enabling OncoSec to address a great unmet medical need
in oncology: anti-PD-1 non-responders. Results from recently
completed clinical studies of TAVO™ have demonstrated a local
immune response, and subsequently, a systemic effect as either a
monotherapy or combination treatment approach. In addition to
TAVO™, OncoSec is identifying and developing new DNA-encoded
therapeutic candidates and tumor indications for use with its
ImmunoPulse® platform. For more information, please visit
www.oncosec.com.
ImmunoPulse® is a registered trademark of OncoSec Medical
Incorporated.
TAVO™ trademark of OncoSec Medical Incorporated.
CONTACT
Investor Relations:
Will O'Connor
Stern Investor Relations
(212) 362-1200
will@sternir.com
Media Relations:
Katie Dodge
JPA Health Communications
(617) 657-1304
kdodge@jpa.com
View original content to download
multimedia:http://www.prnewswire.com/news-releases/oncosec-to-present-at-thinkequity-conference-2019-300839473.html
SOURCE OncoSec Medical Incorporated